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erase 45U/kg). Non significative differences implies overlapped confidence intervals 
for the three therapies in all the efficacy endpoints. ConClusions: This analysis 
suggests a comparable effect of the velaglucerase and taliglucerase on platelet count 
increase, as well as a comparable effect of the three enzymes approved for Gaucher 
disease on Hemoglobin concentration increase, Liver and Spleen volume reduction.
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objeCtives: Opioids have been extensively used in the treatment of oncological 
pain for many years. Due to various therapeutic doses and imprecise measure-
ments of the reduction of pain, it is difficult to make meta-analysis. There are 
only a few precise systematic reviews assessing efficacy of pain medicines (espe-
cially meta-analysis). The study goal was to assess the quality of published data 
of oncological pain treatment and create a meta-analysis when it is possible. It 
has been led in the context of a limited amount of meta-analysis for the opioid 
preparations’ use. Methods: Opioids have been extensively used in the treat-
ment of oncological pain for many years. Due to various therapeutic doses and 
imprecise measurements of the reduction of pain, it is difficult to make meta-
analysis. There are only a few precise systematic reviews assessing efficacy of pain 
medicines (especially meta-analysis). The study goal was to assess the quality of 
published data of oncological pain treatment and create a meta-analysis when 
it is possible. It has been led in the context of a limited amount of meta-analysis 
for the opioid preparations’ use. Results: The primary research provided data 
of high quality. The average Jadad scale rating for all primary publications was 
equal to 3.43. The individual studies presented the effectiveness of individual drugs. 
However, their variation with respect to the scale assessing either pain intensity 
or diversity of a population makes the presentation of meta-analysis impossible to 
be presented. ConClusions: Oncology pain treatment has been assessed in high 
number of published studies. However due to their heterogeneity the meta-analisis 
methodology is limited to be used.
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objeCtives: The incidence is 87% of hemophilia and often leads to disability (90% 
of patients). WHO recommends annual demand of 1 patient of 30 000 IU of factor 
VIII, but in Ukraine with a national program funded an average 5786 IU per year 
(20% of the need). In Ukraine, began production of the domestic drug factor VIII 
“BioKlot A” from 2012. The aim was to determine the effectiveness of substitution 
treatment “BioKlot A” native medicine in the treatment of patients with hemophilia 
A. Methods: In a pilot clinical study examined 168 patients diagnosed with hemo-
philia A severe form of male, aged 18-52 years, who were hospitalized. Experimental 
group received “BioKlot A” control group – “Oktanat” in equal doses of 40 IU / kg / 
day during the first day, 20 IU / kg / day - the next day. All patients were determined 
by the intensity of joint pain, joint swelling index, joint circumference, blood count, 
and others criteria. Results: Within 24 hours after “BioKlot A” (average dose rate 
of 10 000 IU) joint pain significantly decreased after 48 hours - the pain disappeared 
and the joint volume decreased by 14% in 72 hours - the amount of diminished 
joint by 22% and increased range of motion by 28%. Time coagulation by Lee-White 
24 hours decreased from 30 ± 0,2 minute to 19 ± 0,2 minute. In the control group, 
the average dose rate amounted to 10750 IU “Oktanat” and dynamics of clinical 
and hematological data were not significantly different from the experimental 
group. ConClusions: The established similar effectiveness of factor VIII “BioKlot 
A” (Ukraine) and “Oktanat” (Austria) with clinical and laboratory criteria. Production 
of factor VIII preparation in Ukraine has significant socio-economic impact, provid-
ing improved quality of life of patients.
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objeCtives: Imatinib and nilotinib are two tyrosine kinase inhibitors (TKI) used in 
the treatment of chronic myeloid leukemia (CML). Recent data reveals that patients 
who achieve deep molecular responses may be able to stop TKI, which has impor-
tant clinical and economic implications. The efficacy of nilotinib was compared 
to imatinib in newly diagnosed patients and the proportion of patients achieving 
deep molecular response MR4.5, after 5 years, was 31% for imatinib and 54% for 
nilotinib. The aim of this analysis was to estimate the number of patients remaining 
in TFR with nilotinib compared with imatinib. Methods: According to STIM trial, 
39% of patients remained in complete molecular response after discontinuation 
of imatinib. In the Stop 2G-TKI study, 62.2% remained in undetectable molecular 
residual disease after nilotinib discontinuation. Based on this data, we developed 
an outcomes model to estimate the number of patients remaining in TFR long term 
after consolidated treatment with nilotinib versus imatinib. It was assumed that 
after 5 years of treatment with imatinib or nilotinib, patients with consistent MR4.5 
are eligible to interrupt treatment. After 12 months, patients who maintain sus-
tained undetectable BCR-ABL will remain in TFR. Results: Considering an annual 
CML incidence of 1.33 per 100,000 patients, of which 8% are intolerant to treatment, 
we estimated 128 de novo CML patients eligible for TKI treatment in Portugal per 
year. For this cohort of patients, treatment with nilotinib would result in an addi-
tional 28 patients in TFR when compared with imatinib (43 versus 15). Given the 
number of patients remaining in TFR, overall treatment costs with nilotinib, after 
country multi-center medical chart-review study of AS patients was conducted 
among rheumatologists in UK/France/Germany/Italy/Spain to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30yrs) and patient volume (incl. 
> 5AS biologic patients/month) and recruited from a large panel to be geographi-
cally representative in each country. Eligible patient charts (≥ 3) were randomly 
selected from a sample of prospective patients visiting each center/practice dur-
ing the screening period. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status/outcomes. Patients 
on adalimumab/etanercept monotherapy were analyzed. Results: 329 eligible 
AS patient charts were abstracted; 141 on adalimumab (male: 89%, age: 41.9yrs, 
average months on adalimumab: 29.5, 95% on first biologic) and 102 on etanercept 
(male: 78%, age: 43.2yrs, average months on etanercept: 32.2, 98% on first biologic). 
Top-3 comorbidites (adalimumab vs. etanercept) were dyslipidemia: 6% (range: 0% 
(Germany) -11% (Italy)) vs. 8% (range: 0% (UK/Germany) -15% (Spain)), obesity: 4% 
(range: 0% (Italy) -7% (Germany)) vs. 6% (range: 0% (UK) -11% (France)), and depres-
sion: 6% (range: 0% (Italy/Spain) -15% (UK)) vs. 5% (range: 0% (Germany/Spain) -7% 
(Italy/France)). Among patients with available data, latest lab measures documented 
were (adalimumab vs. etanercept): ESR: 15.1mm/h (range: 11.6 (Germany) - 23.6 
(Italy)) vs. 13.6mm/h (range: 8.0 (Germany) -19.2 (Italy)), CRP: 6.7mg/dl (range: 2.6 
(Spain) -8.9 (France)) vs. 7.3mg/dl (range: 1.9 (Germany) -10.0 (Italy)), rheumatoid 
factor-positive: 6% (range: 0% (Spain) -10% (Germany/Italy)) vs. 10% (range: 0% (UK) 
-19% (Italy)). Latest disease severity measures documented were (adalimumab vs. 
etanercept): Swollen Joint Counts: 0.8 (range: 0.1 (Germany) -1.4 (UK)) vs. 0.5 (range: 
0.3 (France) -0.9 (Italy)), Tender Joint Counts: 1.2 (range: 0.5 (Germany) -1.9 (Italy)) 
vs. 1.1 (range: 0.4 (France) -2.1 (Italy)), HAQ: 1.1 (range: 0.7 (Spain) -1.5 (UK)) vs. 1.3 
(range: 1.0 (France) -3.0 (Germany)). ConClusions: Among AS patients receiving 
adalimumab or etanercept monotherapy, disease severity differed within the EU5, 
with patients on adalimumab, and patients in Italy, having marginally higher burden 
and poorer outcomes. Factors influencing the observed patterns and the impact 
of specific biologic treatments on these observations warrant further scrutiny to 
optimize therapeutic interventions and improve outcomes.
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objeCtives: Amfepramone is an anorectic drug used for the short-term treat-
ment of obesity; however, its efficacy and safety in the long-term has been scarcely 
studied. To determine the efficacy and safety of long-acting amfepramone treat-
ment in Mexican adult obese patients by a double blind, randomized and placebo-
controlled clinical trial study. Methods: One hundred and fifty six volunteers 
with a body mass index (BMI) greater than 30 kg/m2 and less than 45 kg/m2 were 
randomized to receive a tablet of 75 mg amfepramone or placebo daily during 6 
months. Primary outcomes were the absolute body weight loss and the percent-
age of patients who achieved at least 5% or 10% weight loss at 3 and 6 months, 
whereas secondary outcomes were the improvement of anthropometric and meta-
bolic parameters. Results: Amfepramone treatment showed a superior efficacy 
to decrease the body weight than placebo at 3 (-4.9 ± 0.25 versus 0.7 ± 0.32 Kg) and 
6 (7.7 ± 0.52 versus 1.1 ± 0.7 Kg) months. In addition, Sixty-four and thirty-four 
patients achieved at least 5% or 10% weight loss, respectively, with amfepramone 
at 6 months, compared with eight and zero patients of placebo. Amfepramone also 
improved BMI and waist circumference, but not waist-hip index (WHI), glucose, 
total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL) and 
triglycerides at 3 and 6 months. Amfepramone produced only mild adverse events 
and they were presented in a greater number than placebo only at 3 months, being 
the main adverse event dry mouth. ConClusions: Data suggest that amfepramone 
is effective and well tolerated in the long-term treatment of Mexican obese patients.
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objeCtives: This study aims to perform a comparative effectiveness study of 
licensed Enzymatic Replacement Therapies (ERT´, taliglucerase, imiglucerase and 
velaglucerase) on the treatment of Gaucher´s disease on adult patients. Methods: 
A systematic review of published clinical trials was performed on three Medical 
databases. Inclusion criteria were randomized, double-blind and phase III clinical 
trials measuring the efficacy of ERT on adult patients. Using meta-analysis method-
ology, the difference in the clinical outputs due the use of a specific ERT in four end-
points was assessed: Hemoglobin concentration increase, platelet count increase, 
Spleen and Liver volume reduction. Since no placebo group is reported in clinical 
trials of orphan drugs, outcomes previous to ERT were considered as control. In this 
study we report the p-value of test for subgroup differences to compare among the 
three alternatives. Results: For the higher dose (60U/kg for the three enzymes), the 
data reported allowed a taliglucerase, velaglucerase and Imiglucerase comparison in 
efficacy measures (except the analysis of imiglucerase in platelet count endpoint). 
Hemoglobin concentration increased a mean of 1.79 g/dL [95% CI 1.08, 2.51; p-value 
for therapy differences= 0.82]. Spleen volume decreased a mean of -5.17 Multiples 
of Normal (MN) [-10.09, -0.25; p-value for therapy differences= 0.90]. ERT showed a 
trend favouring liver volume reduction, -0.28 MN [-0.57, 0.01; p-value for therapy 
differences= 0.80] and increased platelet count, 33.11x109/L [-1.67, 67.89; p-value for 
therapy differences= 0.74]. However, for data limitations, we were unable to perform 
the comparison for the lower dose (taliglucerase and imiglucerase 30U/kg, velagluc-
